Publication of Circular and Notice of GM

RNS Number : 4748S

Polarean Imaging PLC

16 March 2021

 

Polarean Imaging plc  

("Polarean" or the "Company")

Publication of Circular and Notice of General Meeting

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces, further to the announcement of 16 March 2021, in compliance with AIM Rule 20 that, a circular has been sent to shareholders giving notice of a General Meeting, the circular is available to view at www.polarean.com in compliance with AIM Rule 26.

The General Meeting is to be held at the Company's offices at 2500 Meridian Parkway (Suite 175), Durham, NC 27713, USA on 6 April 2021 at 2.00 p.m. (9.00 a.m. EDT).

Enquiries:

Polarean Imaging plc	www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer  Chuck Osborne, Chief Financial Officer Jonathan Allis, Chairman	Via Walbrook PR
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)		[phone]
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)
Nick Adams / Fred Walsh (Corporate Broking)
Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone]

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (¹²⁹Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

END

 

 

MSCJFMRTMTJBBJB